#USA #New York #Securities Fraud #Pomerantz #Zynex

Pomerantz Law Firm Investigates Claims on Behalf of Zynex, Inc. Investors

In a significant development for shareholders, the Pomerantz Law Firm has initiated an investigation into claims on behalf of investors of Zynex, Inc. (NASDAQ: ZYXI). This investigation particularly focuses on whether Zynex and its executives have committed securities fraud or other unlawful business practices. Investors impacted by these issues are urged to reach out to attorney Danielle Peyton at Pomerantz for further guidance.

Background on Zynex, Inc.

Zynex, Inc. is a notable player in the medical technology landscape, best known for its innovative electrotherapy and pain management devices. Recently, the company disclosed its fourth quarter and full-year financial results for 2024, which showcased alarming revenue shortfalls attributed to delayed payments from various payers. This lack of expected revenue has raised significant concerns among investors regarding the company’s financial stability and transparency.

On March 11, 2025, the company revealed that a substantial portion of its annual revenue—between 20% to 25%—is derived from Tricare, the healthcare program catering to uniformed service members. However, Zynex reported that Tricare had temporarily halted payments while reviewing prior claims, further exacerbating the company’s financial predicament. As a result of this news, the stock price experienced a drastic decline of $3.59 per share, translating to a staggering 51.3% drop and bringing the closing price down to $3.41 on March 12, 2025.

Implications for Investors

The investigation by Pomerantz LLP raises critical questions regarding potential transparency issues within Zynex's financial practices. Given the significant revenue reliance on Tricare, the temporary suspension of these payments has further complicated the financial outlook of the company, leading to fears of ongoing instability.

With over 85 years of experience, Pomerantz has a well-documented history of pursuing justice for investors and victims of corporate misconduct. The firm’s track record in securities class actions makes it a formidable advocate for shareholders who feel wronged. They have successfully recovered substantial damages in multiple cases and continue to take a staunch stand against securities fraud.

Investors are encouraged to stay informed and consider their legal options amid this ongoing situation at Zynex. The implications of the investigation could result in a broader exploration of the company’s operations and financial strategies, as well as an increased focus on corporate governance and ethical business conduct within the sector.

Conclusion

As Pomerantz Law Firm delves deeper into the claims against Zynex, it remains imperative for investors to stay vigilant. Continuous updates on both the legal proceedings and Zynex’s financial performances will be crucial in determining the future of the company and its stock value. For those affected, reaching out to legal professionals is a prudent step towards understanding one's rights and options.